Sector Update: Health Care

By
A A A

Health-care shares were generally mixed in pre-market trading Monday.

Compugen ( CGEN ) shares were up 2% in recent pre-market trading, after the drug-discovery company said it achieved the initial milestone in the cancer-immunotherapy collaboration it entered last year with Bayer HealthCare. The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen.

Bristol-Myers Squibb ( BMY ) said Japan has approved Daklinza and Sunvepra to treat patients with genotype 1 chronic hepatitis C virus infection, including those with compensated cirrhosis. The Daklinza, Sunvepra Dual Regimen is Japan's first all-oral, interferon and ribavirin-free treatment regimen for patients with genotype 1 chronic hepatitis C virus infection, including those with compensated cirrhosis. It noted of the 1.2 million people living with HCV in Japan, approximately 70% have genotype 1b.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: CGEN , BMY

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

How to Fire Your Adviser
How to Fire Your Adviser            

Stocks

Referenced

Most Active by Volume

75,750,465
  • $16.77 ▲ 0.36%
59,791,764
  • $101.58 ▲ 0.71%
38,720,622
  • $42.59 ▼ 0.28%
37,416,417
  • $46.52 ▼ 0.51%
35,101,793
  • $16.28 ▲ 0.74%
34,987,975
  • $99.53 ▲ 0.15%
33,760,830
  • $3.63 ▲ 0.69%
32,148,671
  • $17.61 ▲ 0.57%
As of 9/17/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com